Open AccessImmunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma
Author(s) -
Cecilia Lezcano,
Melissa Pulitzer,
Andrea P. Moy,
Travis J. Hollmann,
Achim A. Jungbluth,
Klaus J. Busam
Publication year - 2019
Publication title -
the american journal of surgical pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 210
eISSN - 1532-0979
pISSN - 0147-5185
DOI - 10.1097/pas.0000000000001393
Subject(s) - melanoma , medicine , nodal , immunohistochemistry , pathology , lymph node , hmb 45 , lymph , nevus , immunostaining , sentinel lymph node , metastatic melanoma , spitz nevus , cancer , cancer research , breast cancer
The distinction of metastatic melanoma from melanocytic nevi in lymph nodes can on occasion be difficult. As diffuse immunohistochemical (IHC) PRAME (PReferentially expressed Antigen in MElanoma) expression is detected in the majority of primary and metastatic melanomas, but rarely in nevi, we reasoned that PRAME could be a useful adjunct marker for the diagnosis of melanocytes in lymph nodes. In this study, we examined 45 nodal melanocytic deposits comprising 30 nodal nevi and 15 melanoma metastases. The latter were diagnostically not straightforward because they either coexisted with nodal nevi or were present in perinodal fibrous tissue. All nodal nevi (30/30) were negative for PRAME, whereas all melanoma metastases (15/15) were diffusely positive for PRAME IHC. We additionally report the novel use of a PRAME/Melan A dual-label immunostain. Our results show that PRAME IHC may be useful in the assessment of diagnostically challenging nodal melanocytic deposits, such as intraparenchymal nodal nevi, metastases confined to the capsular fibrous tissue, or in the setting of small metastases coexisting with a nodal nevus in the same lymph node.